RecruitingPhase 1NCT06544720
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas
Sponsor
The Affiliated Hospital of Qingdao University
Enrollment
18 participants
Start Date
Aug 2, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Greater than or equal to 18 years of age
- HPV associated carcinomas
- Patients must have at least one measurable lesion defined by RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Exclusion Criteria4
- Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.
- Patients with active autoimmune diseases.
- Patient has a known active Hepatitis B or Hepatitis C.
- Other severe medical conditions that may limit subject\'s participation in this trial.
Interventions
BIOLOGICALSCG142 TCR-T cells
Monotherapy of SCG142
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06544720
Related Trials
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT049774538 locations
Feasibility Study of CBCT for IGRT in Cancer Patients
NCT066812334 locations
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
NCT064930194 locations
Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic Radiotherapy
NCT040944541 location